Supplementary Figures S1-S4 from Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non–Small Cell Lung Cancer

Supplementary Figures S1-S4.</p

Analysis of the two main TGFβ1 receptors in tissue samples of adenomas and adenocarcinomas.

<p>TGFβ1RI: TGFβ1 receptor I; TGFβ1RII: TGFβ1 receptor II.</p><p>TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma.</p><p>In brackets percentages of patients with alteration of the TGFβ1 receptor system. Minimal or low grade immunostaining was taken as an index of receptors’alteration.</p

Evaluation of serum levels of TGFβ1 and VEGF during colorectal carcinogenesis.

<p>The levels of TGFβ1 (A) and VEGF (B) were measured in controls and patient groups (N: control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma). TGFβ1 and VEGF were detected by ELISA and values expressed as ng/ml and pg/ml serum, respectively (see materials and methods). A: dots correspond to single TGFβ1 values and black lines represent the mean values within the experimental groups. Mean values ± SEM: N 6.3±0.4; TA 7.2±0.45; TVA 6.3±0.6; IAC 6.9±0.3; IIAC 4.9±0.3; IIIAC 4.4±0.3; IVAC 5.7±0.5. *Significantly different versus control group (p<0.05). B: dots correspond to single VEGF values and black lines represent the mean values within the experimental groups. Mean values ± SEM: N 227.0±18.7; TA 215.2±31.3; TVA 221.1±36.4; IAC 216.3±34.4; IIAC 205.0±26.6; IIIAC 266.5±38.6; IVAC 295.2±70.2.</p

Evaluation of serum levels of IL-8 and IL-6 during colorectal carcinogenesis.

<p>The levels of IL-8 (A) and IL-6 (B) were measured in controls and patient groups (N: control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma). IL-8 and IL-6 were detected by ELISA and values expressed as pg/ml serum (see materials and methods). A: dots correspond to IL-8 single values and black lines represent the mean values within the experimental groups. Mean values ± SEM: N 17.0±2.5; TA 15.9±3.7; TVA 18.4±2.2; IAC 25.4±4.8; IIAC 38.7±5.1; IIIAC 37.2±5.7; IVAC 30.5±5.7. *Significantly different versus control group (p<0.05). B: dots correspond to single IL-6 values and black lines represent the mean values within experimental groups. Mean values ± SEM: N 247.1±55; TA 375.9±54; TVA 407.9±80; IAC 237.9±68; IIAC 472.3±89; IIIAC 521.3±152; IVAC 436.3±118. *Significantly different versus control group (p<0.05).</p

Supplementary Table 1 from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

Supplementary Table 1 from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplati

Supplementary Figure 1 from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

Supplementary Figure 1 from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplati

Distribution and expression of MMP-9 on paraffin embedded CRC tissue sections.

<p>A: a representative image of carcinoma tissue at stage III showed strong staining for MMP-9, localized in the cytoplasm of both tumor cells and inflammatory cells (10x/0.22 objective). For experimental details see materials and methods. B: higher magnification of a MMP-9 positive area of the same cancer section (40x/0.65 objective). The images were obtained using Digital Microscope DMD Leica, Leica Microsystems, Milan, Italy.</p

Evaluation of serum MMP activity and levels during colorectal carcinogenesis.

<p>A: active forms of MMP-2 and MMP-9 are shown in a representative gelatin zymography. B: MMP-9 activation in the serum was evaluated by densitometric analysis as percentage of active MMP-9 compared to controls (taken as 100%). Dots correspond to the activated MMP-9 value for each subject and black lines represent mean values within the experimental groups. Mean values ± SEM: TA 120±3.9; TVA 121±8.5; IAC 151.63±17.2; IIAC 163.81±16.6; IIIAC 164.2±10.6; IVAC 129.0±13.0. *Significantly different versus control group (p<0.01). C: serum levels of MMP-9 protein were detected by ELISA and expressed as ng/ml serum. Dots correspond to the MMP-9 value for each subject and black lines represent the mean values within the experimental groups. Mean values ± SEM: N 1.5±0.2; TA 1.9±0.3; TVA 1.9±0.3; I AC 2.7±0.3; IIAC 2.8±0.3; IIIAC 3.0±0.5; IVAC 2.6±0.4. *Significantly different versus control group (p<0.05). N: control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma.</p

Supplementary Figure 1 from Ribonucleotide Reductase Large Subunit (<i>RRM1</i>) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer

PDF file, 30KB, ERCC1 gene expression under mitotane treatment in ACC cancer cells.</p

Supplementary Figure Legend from Ribonucleotide Reductase Large Subunit (<i>RRM1</i>) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer

PDF file, 43KB.</p